Sale

Nanomedicine Market

Global Nanomedicine Market Size, Price, Analysis: By Product Type: Therapeutics, Regenerative Medicine, Vaccines, Others; By Type: Nanoparticles, Nano shells, Nano Devices, Others; By Modality: Diagnostic, Treatment; By Indications: Drug Delivery, Diagnostic Imaging, Tissue Regeneration, Others; Regional Analysis; Supplier Landscape; 2024-2032

Global Nanomedicine Market Outlook

The global nanomedicine market size attained a value of USD 266.84 billion in 2023. The market is anticipated to grow at a CAGR of 11.6% during the forecast period of 2024-2032 to attain a value of USD 716.51 billion by 2032.

 

Global Nanomedicine Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Increasing Demand for Nanomedicines to Augment the Market Growth

The increase in the demand for nanomedicines can be attributed to the rapidly increasing applications of nanomaterials like nanocapsules as well as nanotubes in drug delivery systems. The demand for nanomedicines is further aided by the increase in the incidences of cancer and cardiovascular diseases, leading to the growth of public and private investments in nanomedicine research and advancements in biodegradable nanoparticles. The cost-effectiveness and fewer side-effects of these therapies are also major drivers of the nanomedicine industry growth.

 

North America to be a Significant Regional Market for Nanomedicine with the Asia Pacific Being One of the Fastest Growing Markets

Due to substantial government spending on nanomedicine research in the United States, the North American nanomedicine industry is expected to be one of the leading markets for nanomedicine in the forecast period of 2024-2032. The increased availability of patented nanomedicine items is credited with the region's growth. In addition to a well-developed healthcare infrastructure and a significant incidence of cancer, nanomedicine is easily accessible in this region, which has aided the market growth further.

The large geriatric population in the Asia Pacific is witnessing high incidence rates of cancer and cardiovascular diseases, which is expected to boost the nanomedicine market in the region. The regional market is expected to be one of the fastest growing markets for nanomedicine. The market growth in the Asia Pacific is expected to be aided by the increase in research grants to tackle life-threatening diseases, with countries like China and Japan leading the way.

 

Nanomedicine: Market Segmentation

Nanomedicine is a segment of nanotechnology that is used to diagnose, treat, monitor, and regulate biological systems. It improves medicine delivery by manipulating materials at the nanoscale. As a result, nanomedicine has aided in the treatment of a variety of illnesses. Nanomedicine is still in its infancy, with numerous items under development. Nanobiotix has identified 230 nanomedicine products that are either marked or in the trial phase. Out of the 230 products, 49 are in the market, and 122 are in the clinical trial phases, either in Phase II or Phase III trials.

 

Global Nanomedicine Market by Segment

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Based on product type, the market can be segmented into:

By application, the market is categorised into:

  • Clinical Oncology
  • Infectious Diseases
  • Clinical Cardiology
  • Orthopaedics
  • Others

On the basis of nanomolecule type, the industry is categorised into:

  • Nanoparticles and Quantum Dots
    • Metal and Metal Compounds
    • Liposomes
    • Polymer and Polymer Drug Conjugate
    • Hydrogel Nanoparticles
    • Dendrimers
    • Inorganic Nanoparticles
  • Nanoshells
  • Nanotubes
  • Nanodevices

The major regional markets of nanomedicine are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

 

Global Nanomedicine Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Increasing Focus on Technological Advancements for Improved Healthcare Services to Bolster the Growth of the Nanomedicine Industry

Currently, the healthcare sector is one of the most important areas where nanotechnology has made significant progress in the detection and treatment of chronic diseases such as cancer, heart disease, and other disorders. Firms researching patch technologies have attracted significant financing as healthcare companies focus on transdermal insulin administration as the industry's emphasis is moving toward transdermal medication delivery. Further, the tailored medication delivery method is being emphasised heavily in order to reduce the risk of side effects. Bypassing the body's defence mechanisms, this method provides reachability with increased efficacy and minimum degradation. Such technological developments and investments are likely to propel the growth of the market in the coming years.

 

Key Industry Players in the Global Nanomedicine Market

The report gives a detailed analysis of the following key players in the global nanomedicine market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • Arrowhead Pharmaceuticals, Inc.
  • Nanospectra Biosciences, Inc.
  • Ablynx N.V.
  • AMAG Pharmaceuticals, Inc.
  • Celgene Corporation
  • Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Product Type
  • Type
  • Modality
  • Indications
  • Region
Breakup by Product Type
  • Therapeutics
  • Regenerative Medicine
  • Vaccines
  • Others
Breakup by Type
  • Nanoparticles
  • Nano shells
  • Nano Devices
  • Others
Breakup by Modality
  • Diagnostic
  • Treatment
Breakup by Indications
  • Drug Delivery
  • Diagnostic Imaging
  • Tissue Regeneration
  • Infectious Disease
  • Orthopedics
  • Neurological disease
  • Oncology
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Abbott
  • Invitae Corporation
  • General Electric Company
  • Leadiant Biosciences, Inc.
  • Johnson & Johnson Services, Inc.
  • Mallinckrodt
  • Merck Sharp & Dohme Corp.
  • Nanosphere Health Sciences, Inc.
  • Pfizer Inc.
  • Celgene Corporation
  • Teva Pharmaceutical Industries Ltd.
  • Gilead Sciences, Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Abbvie Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Luminex Corporation
  • Lilly
  • Nanobiotix
  • Sanofi
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope
    1.4    Research Methodology
2    Executive Summary
3    Global Nanomedicine Market Overview

    3.1    Global Nanomedicine Market Historical Value (2017-2023) 
    3.2    Global Nanomedicine Market Forecast Value (2024-2032)
4    Global Nanomedicine Market Landscape
    4.1    Global Nanomedicine Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Global Nanomedicine Product Landscape
        4.2.1    Analysis by Product Type
        4.2.2    Analysis by Modality
        4.2.3    Analysis by Indications
5    Global Nanomedicine Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
    5.3    Porter’s Five Forces Model 
    5.4    Key Demand Indicators
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends 
    5.7    Value Chain Analysis
6    Global Nanomedicine Market Segmentation
    6.1    Global Nanomedicine Market by Product Type
        6.1.1    Market Overview
        6.1.2    Therapeutics
        6.1.3    Regenerative Medicine
        6.1.4    Vaccines
        6.1.5    Others
    6.2    Global Nanomedicine Market by Type
        6.2.1    Market Overview
        6.2.2    Nanoparticles
            6.2.2.1    Gold Nanoparticles
            6.2.2.2    Iron Oxide Nanoparticles
            6.2.2.3    Hydrogel Nanoparticles
            6.2.2.4    Others
        6.2.3    Nano shells
        6.2.4    Nano Devices
        6.2.5    Others
    6.3    Global Nanomedicine Market by Modality
        6.3.1    Market Overview
        6.3.2    Diagnostic 
        6.3.3    Treatment 
    6.4    Global Nanomedicine Market by Indications
        6.4.1    Market Overview
        6.4.2    Drug Delivery
        6.4.3    Diagnostic Imaging
        6.4.4    Tissue Regeneration
        6.4.5    Infectious Disease
        6.4.6    Orthopedics
        6.4.7    Neurological disease
        6.4.8    Oncology
        6.4.9    Others
    6.5    Global Nanomedicine s Market by Region
        6.5.1    Market Overview
        6.5.2    North America 
        6.5.3    Europe
        6.5.4    Asia Pacific
        6.5.5    Latin America
        6.5.6    Middle East and Africa
7    North America Nanomedicine Market
    7.1    Market Share by Country
    7.2    United States of America
    7.3    Canada
8    Europe Nanomedicine Market
    8.1    Market Share by Country
    8.2    United Kingdom
    8.3    Germany
    8.4    France
    8.5    Italy
    8.6    Others
9    Asia Pacific Nanomedicine Market
    9.1    Market Share by Country
    9.2    China
    9.3    Japan
    9.4    India
    9.5    ASEAN
    9.6    Australia
    9.7    Others
10    Latin America Nanomedicine Market
    10.1    Market Share by Country
    10.2    Brazil
    10.3    Argentina
    10.4    Mexico
    10.5    Others
11    Middle East and Africa Nanomedicine Market
    11.1    Market Share by Country
    11.2    Saudi Arabia
    11.3    United Arab Emirates
    11.4    Nigeria
    11.5    South Africa
    11.6    Others
12    Patent Analysis
    12.1    Analysis by Type of Patent
    12.2    Analysis by Publication year
    12.3    Analysis by Issuing Authority
    12.4    Analysis by Patent Age
    12.5    Analysis by CPC Analysis
    12.6    Analysis by Patent Valuation 
    12.7    Analysis by Key Players
13    Grants Analysis
    13.1    Analysis by year
    13.2    Analysis by Amount Awarded
    13.3    Analysis by Issuing Authority
    13.4    Analysis by Grant Application
    13.5    Analysis by Funding Institute
    13.6    Analysis by NIH Departments
    13.7    Analysis by Recipient Organization 
14    Funding Analysis
    14.1    Analysis by Funding Instances
    14.2    Analysis by Type of Funding
    14.3    Analysis by Funding Amount
    14.4    Analysis by Leading Players
    14.5    Analysis by Leading Investors
    14.6    Analysis by Geography
15    Partnership and Collaborations Analysis
    15.1    Analysis by Partnership Instances
    15.2    Analysis by Type of Partnership
    15.3    Analysis by Leading Players
    15.4    Analysis by Geography
16    Regulatory Framework
    16.1    Regulatory Overview
    16.1.1    US FDA
    16.1.2    EU EMA
    16.1.3    INDIA CDSCO
    16.1.4    JAPAN PMDA
    16.1.5    Others
17    Supplier Landscape
    17.1    Abbott
        17.1.1    Financial Analysis
        17.1.2    Product Portfolio
        17.1.3    Demographic Reach and Achievements
        17.1.4    Mergers and Acquisitions
        17.1.5    Certifications
    17.2    Invitae Corporation
        17.2.1    Financial Analysis
        17.2.2    Product Portfolio
        17.2.3    Demographic Reach and Achievements
        17.2.4    Mergers and Acquisitions
        17.2.5    Certifications
    17.3    General Electric Company
        17.3.1    Financial Analysis
        17.3.2    Product Portfolio
        17.3.3    Demographic Reach and Achievements
        17.3.4    Mergers and Acquisitions
        17.3.5    Certifications
    17.4    Leadiant Biosciences, Inc.
        17.4.1    Financial Analysis
        17.4.2    Product Portfolio
        17.4.3    Demographic Reach and Achievements
        17.4.4    Mergers and Acquisitions
        17.4.5    Certifications
    17.5    Johnson & Johnson Services, Inc.
        17.5.1    Financial Analysis
        17.5.2    Product Portfolio
        17.5.3    Demographic Reach and Achievements
        17.5.4    Mergers and Acquisitions
        17.5.5    Certifications
    17.6    Mallinckrodt
        17.6.1    Financial Analysis
        17.6.2    Product Portfolio
        17.6.3    Demographic Reach and Achievements
        17.6.4    Mergers and Acquisitions
        17.6.5    Certifications
    17.7    Merck Sharp & Dohme Corp.
        17.7.1    Financial Analysis
        17.7.2    Product Portfolio
        17.7.3    Demographic Reach and Achievements
        17.7.4    Mergers and Acquisitions
        17.7.5    Certifications
    17.8    Nanosphere Health Sciences, Inc.
        17.8.1    Financial Analysis
        17.8.2    Product Portfolio
        17.8.3    Demographic Reach and Achievements
        17.8.4    Mergers and Acquisitions
        17.8.5    Certifications
    17.9    Pfizer Inc.
        17.9.1    Financial Analysis
        17.9.2    Product Portfolio
        17.9.3    Demographic Reach and Achievements
        17.9.4    Mergers and Acquisitions
        17.9.5    Certifications
    17.10    Celgene Corporation
        17.10.1    Financial Analysis
        17.10.2    Product Portfolio
        17.10.3    Demographic Reach and Achievements
        17.10.4    Mergers and Acquisitions
        17.10.5    Certifications
    17.11    Teva Pharmaceutical Industries Ltd.
        17.11.1    Financial Analysis
        17.11.2    Product Portfolio
        17.11.3    Demographic Reach and Achievements
        17.11.4    Mergers and Acquisitions
        17.11.5    Certifications
    17.12    Gilead Sciences, Inc.
        17.12.1    Financial Analysis
        17.12.2    Product Portfolio
        17.12.3    Demographic Reach and Achievements
        17.12.4    Mergers and Acquisitions
        17.12.5    Certifications
    17.13    Amgen Inc.
        17.13.1    Financial Analysis
        17.13.2    Product Portfolio
        17.13.3    Demographic Reach and Achievements
        17.13.4    Mergers and Acquisitions
        17.13.5    Certifications
    17.14    Bristol-Myers Squibb Company
        17.14.1    Financial Analysis
        17.14.2    Product Portfolio
        17.14.3    Demographic Reach and Achievements
        17.14.4    Mergers and Acquisitions
        17.14.5    Certifications
    17.15    Abbvie Inc.
        17.15.1    Financial Analysis
        17.15.2    Product Portfolio
        17.15.3    Demographic Reach and Achievements
        17.15.4    Mergers and Acquisitions
        17.15.5    Certifications
    17.16    Novartis AG
        17.16.1    Financial Analysis
        17.16.2    Product Portfolio
        17.16.3    Demographic Reach and Achievements
        17.16.4    Mergers and Acquisitions
        17.16.5    Certifications
    17.17    F. Hoffmann-La Roche Ltd
        17.17.1    Financial Analysis
        17.17.2    Product Portfolio
        17.17.3    Demographic Reach and Achievements
        17.17.4    Mergers and Acquisitions
        17.17.5    Certifications
    17.18    Luminex Corporation
        17.18.1    Financial Analysis
        17.18.2    Product Portfolio
        17.18.3    Demographic Reach and Achievements
        17.18.4    Mergers and Acquisitions
        17.18.5    Certifications
    17.19    Lilly
        17.19.1    Financial Analysis
        17.19.2    Product Portfolio
        17.19.3    Demographic Reach and Achievements
        17.19.4    Mergers and Acquisitions
        17.19.5    Certifications
    17.20    Nanobiotix
        17.20.1    Financial Analysis
        17.20.2    Product Portfolio
        17.20.3    Demographic Reach and Achievements
        17.20.4    Mergers and Acquisitions
        17.20.5    Certifications
    17.21    Sanofi
        17.21.1    Financial Analysis
        17.21.2    Product Portfolio
        17.21.3    Demographic Reach and Achievements
        17.21.4    Mergers and Acquisitions
        17.21.5    Certifications
18    Global Nanomedicine Market - Distribution Model (Additional Insight)
    18.1    Overview 
    18.2    Potential Distributors 
    18.3    Key Parameters for Distribution Partner Assessment 
19    Key Opinion Leaders (KOL) Insights (Additional Insight)
20    Company Competitiveness Analysis (Additional Insight)

    20.1    Very Small Companies
    20.2    Small Companies
    20.3    Mid-Sized Companies
    20.4    Large Companies
    20.5    Very Large Companies
21    Payment Methods (Additional Insight)
    21.1    Government Funded
    21.2    Private Insurance
    21.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The nanomedicine market was valued at USD 266.84 billion in 2023.

The market is expected to grow at a CAGR of 11.6% from 2024 to 2032 to reach a value of USD 716.51 billion by 2032.

The major drivers of the industry, such as emerging technologies for drug delivery, increase in adoption of nanomedicine across varied applications, rise in government support and funding, growth in the need for therapies with fewer side effects, and cost-effectiveness of therapies, are expected to aid the market growth.

The key market trends guiding the growth of the industry include out-licensing of nanodrugs and growth of the healthcare facilities.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The leading product types of nanomedicine in the industry are therapeutics, regenerative medicine, in-vitro diagnostics, in-vivo diagnostics, and vaccines.

The major application segment in the market are clinical oncology, infectious diseases, clinical cardiology, and orthopaedics, among others.

The significant nanomolecule types in the industry are nanoparticles and quantum dots, nanoshells, nanotubes, and nanodevices.

The major players in the industry are Arrowhead Pharmaceuticals, Inc., Nanospectra Biosciences, Inc., Ablynx N.V., AMAG Pharmaceuticals, Inc., and Celgene Corporation, among others.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER